IFNG and neoplasm: Although the in vivo anti-tumor efficacy mechanisms of SOT101 and Daratumumab have not been characterized in this study in detail, it is hypothesized that activated NK cell-mediated ADCC, and macrophage-dependent cellular phagocytosis (ADCP) underlie the observed anti-tumor effects together with SOT101-induced activation of NK cell cytotoxic functions, IFN-γ production and the expression of activating receptors.